Results from a Phase 1 clinical trial evaluating the drug rezatapopt in cancer patients were published today in the New England Journal of Medicine, according to a statement released by PMV Pharmaceuticals.
The study, detailed in the February 26, 2026, issue of the journal, represents the first-in-human evaluation of rezatapopt, a small molecule therapy designed to target the p53 protein. PMV Pharma, which is developing the drug, indicated the findings are from the initial portion of the ongoing Phase 1/2 PYNNACLE study.
Separately, research published in the same issue of the New England Journal of Medicine details a promising combination therapy for HER2-positive metastatic breast cancer. The study investigated the efficacy of trastuzumab deruxtecan, when used in conjunction with pertuzumab, for patients who have not responded to other treatments. Researchers found the combination may offer a new treatment pathway for these patients.
The New England Journal of Medicine’s February 26th issue, Volume 394, Issue 9, includes research spanning a range of medical advancements, according to News Directory 3.
PMV Pharmaceuticals’ announcement did not disclose specific clinical outcomes from the rezatapopt trial, only noting the publication of the Phase 1 data. Further results from the PYNNACLE study are anticipated as the trial progresses.
